Muroyama Ryosuke

ムロヤマリョウスケ | Muroyama Ryosuke

Research theme for competitive and other funds (5)：

2019 - 2022 肝癌感受性遺伝子MICAのシェダーゼ阻害を基盤とした新規治療薬の探索
2018 - 2021 Elucidation of the role of NKG2D ligands in HBV-related hepatocellular carcinoma
2012 - 2015 Functional analysis of MICA in hepatitis C virus-induced hepatocellular carcinoma and its therapeutic application
2011 - 2012 The regulation of miR-122 which is involved in Hepatitis C virus replication and interferon treatment response
2008 - 2010 Interferon stimulated genes and its polymorphisms determining Hepatitis C virus replication and pathogenesis of hepatitis C

Papers (63)：

Hiroaki Kanzaki, Sadahisa Ogasawara, Tomomi Okubo, Norio Itokawa, Ryohei Yoshino, Kentaro Fujimoto, Tadayoshi Kogure, Sae Yumita, Takamasa Ishino, Keita Ogawa, et al. Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis. Drugs - real world outcomes. 2023
Ryuta Kojima, Shingo Nakamoto, Tadayoshi Kogure, Yaojia Ma, Keita Ogawa, Terunao Iwanaga, Na Qiang, Junjie Ao, Ryo Nakagawa, Ryosuke Muroyama, et al. Re-analysis of hepatitis B virus integration sites reveals potential new loci associated with oncogenesis in hepatocellular carcinoma. World Journal of Virology. 2023. 12. 3. 209-220
Na Qiang, Junjie Ao, Masato Nakamura, Tetsuhiro Chiba, Yuko Kusakabe, Tatsuya Kaneko, Akane Kurosugi, Tadayoshi Kogure, Yaojia Ma, Jiaqi Zhang, et al. Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma. International immunopharmacology. 2023. 118. 110068-110068
Sae Yumita, Sadahisa Ogasawara, Miyuki Nakagawa, Susumu Maruta, Tomomi Okubo, Norio Itokawa, Yotaro Iino, Masamichi Obu, Yuki Haga, Atsuyoshi Seki, et al. Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice. BMC gastroenterology. 2023. 23. 1. 101-101
Naoya Kanogawa, Sadahisa Ogasawara, Susumu Maruta, Yotaro Iino, Masamichi Obu, Takamasa Ishino, Keita Ogawa, Sae Yumita, Terunao Iwanaga, Hidemi Unozawa, et al. Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma. BMC gastroenterology. 2023. 23. 1. 70-70

ｍore...

MISC (26)：

井上将法, 小笠原定久, 石野貴雅, 小川慶太, 岩永光巨, 宇野澤秀美, 弓田冴, 中川美由貴, 藤原希彩子, 神崎洋彰, et al. 脈管侵襲を伴う進行肝細胞癌における薬物療法と適切な治療効果判定の検討. 肝臓. 2022. 63. Suppl.3. A780-A780
佐久間崇文, 中村昌人, 千葉哲博, 敖俊傑, 強娜, 小川慶太, 岩永光巨, 菅元泰, 藤田尚人, 神崎洋彰, et al. 新規食餌誘導性非アルコール性脂肪性肝疾患モデルマウスの構築と経口血糖降下薬による治療効果の検証. 肝臓. 2022. 63. Suppl.1. A310-A310
弓田冴, 小笠原定久, 叶川直哉, 岩永光巨, 宇野澤秀美, 藤原希彩子, 中川美由貴, 佐久間崇文, 藤田尚人, 神崎洋彰, et al. 進行肝細胞癌におけるGd-EOB-DTPA-enhanced MRI肝細胞相・高信号結節のアテゾリズマブ・ベバシズマブ併用療法の有効性の検証. 肝臓. 2022. 63. Suppl.1. A327-A327
叶川直哉, 小笠原定久, 岩永光巨, 宇野澤秀美, 中川美由貴, 藤原希彩子, 佐久間崇文, 藤田尚人, 神崎洋彰, 興梠慧輔, et al. 今後のトレンドを加味した肝細胞癌治療後のフォローアップ間隔の緩和の可能性の検討. 肝臓. 2022. 63. Suppl.1. A422-A422
小川慶太, 千葉哲博, 岩永光巨, 菅元泰, 強娜, 敖俊傑, 佐久間崇文, 藤田尚人, 神崎洋彰, 興梠慧輔, et al. 肝細胞癌におけるCTNNB1遺伝子変異とアテゾリズマブ/ベバシズマブ併用療法の初期治療効果の関連性の検討. 肝臓. 2022. 63. Suppl.1. A336-A336

ｍore...

Books (2)：

創薬研究者がこれだけは知っておきたい最新のウイルス学
技術情報協会 2021 ISBN:9784861048555
肝炎ウイルス-B型・C型
医薬ジャーナル社 2012 ISBN:9784753225736

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page